Marzano Luigi, Husain-Syed Faeq, Reis Thiago, Ronco Claudio, Zanella Monica
Internal Medicine Unit, San Bortolo Hospital, U.L.S.S. 8 Berica - Viale Rodolfi 37, 36100, Vicenza, Italy.
Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstrasse 33, Giessen, Germany.
J Hum Hypertens. 2023 Jul;37(7):532-541. doi: 10.1038/s41371-022-00731-8. Epub 2022 Jul 26.
The Aldosteronoma Resolution Score (ARS) is the most studied scoring system for predicting the high likelihood of hypertension cure after adrenalectomy for unilateral primary aldosteronism (PA). However, the ARS's accuracy in PA patients worldwide is uncertain. We aimed to perform a meta-analysis of the accuracy, discrimination, and calibration of the ARS using stratum-specific likelihood ratios (SSLR) by organizing available data from cohort studies. We searched PubMed, Embase (Ovid), the Cochrane CENTRAL, Web of Science to November 2021 according to PRISMA statement. The quality assessment used adapted TRIPOD and PROBAST criteria. Thirteen studies comprising 2158 PA patients from North America (43%), Europe (32%), Asia (22%), and other continents, were included. The pooled estimate of the area under the receiver operating characteristic curve for all studies was 0.77 (95% CI: 0.73-0.81), and the ratio of the observed to expected complete resolution of hypertension (CRH) for all studies was 0.9 (95% CI: 0.8-1.0). The summary estimates of the SSLR for all studies were 0.31, 0.89, and 3.1, for the low (ARS 0-1), medium (ARS 2-3), and high-likelihood group (ARS 4-5) of CRH, respectively. However, substantial heterogeneity existed among studies. Follow-up period, and adrenalectomy AVS (adrenal vein sampling)-guided served as potential sources of heterogeneity for quantitative studies, which were measurement and reference standard for qualitative studies selection. In conclusion, in patients with unilateral PA, the ARS is currently an accurate prediction tool, the easiest and cheapest, for identifying long-term high likelihood of CRH after adrenalectomy, particularly when the adrenalectomy is AVS-guided.
醛固酮瘤缓解评分(ARS)是用于预测单侧原发性醛固酮增多症(PA)患者肾上腺切除术后高血压治愈高可能性的研究最多的评分系统。然而,ARS在全球PA患者中的准确性尚不确定。我们旨在通过整理队列研究中的可用数据,使用分层特异性似然比(SSLR)对ARS的准确性、区分度和校准进行荟萃分析。我们根据PRISMA声明检索了截至2021年11月的PubMed、Embase(Ovid)、Cochrane CENTRAL、Web of Science。质量评估采用了改编后的TRIPOD和PROBAST标准。纳入了13项研究,共2158例来自北美(43%)、欧洲(32%)、亚洲(22%)和其他大洲的PA患者。所有研究的受试者工作特征曲线下面积的合并估计值为0.77(95%CI:0.73 - 0.81),所有研究中观察到的与预期的高血压完全缓解(CRH)的比率为0.9(95%CI:0.8 - 1.0)。所有研究中CRH低(ARS 0 - 1)、中(ARS 2 - 3)、高可能性组(ARS 4 - 5)的SSLR汇总估计值分别为0.31、0.89和3.1。然而,研究之间存在显著异质性。随访期以及肾上腺切除术AVS(肾上腺静脉采样)引导是定量研究异质性的潜在来源,是定性研究选择的测量和参考标准。总之,对于单侧PA患者,ARS目前是一种准确的预测工具,是识别肾上腺切除术后CRH长期高可能性的最简单、最便宜的工具,特别是当肾上腺切除术由AVS引导时。